Prothena Corp. (NASDAQ:PRTA) shares traded up 4.3% during trading on Thursday . The company traded as high as $45.68 and last traded at $45.31, with a volume of 334,703 shares trading hands. The stock had previously closed at $43.46.

A number of research analysts have recently commented on the company. Zacks Investment Research upgraded Prothena Corp. from a “sell” rating to a “hold” rating in a research note on Friday, May 6th. Credit Suisse Group AG restated a “buy” rating on shares of Prothena Corp. in a research note on Wednesday, May 4th. Wedbush restated an “outperform” rating and issued a $77.00 target price on shares of Prothena Corp. in a research note on Tuesday, July 5th. Barclays PLC assumed coverage on Prothena Corp. in a research note on Friday, May 13th. They issued an “overweight” rating and a $60.00 target price for the company. Finally, Royal Bank Of Canada restated a “buy” rating on shares of Prothena Corp. in a research note on Friday, June 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $74.60.

The stock’s 50-day moving average price is $43.35 and its 200 day moving average price is $42.16. The company’s market capitalization is $1.67 billion.

Prothena Corp. (NASDAQ:PRTA) last posted its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.81) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by $0.04. On average, equities analysts forecast that Prothena Corp. will post ($3.72) EPS for the current fiscal year.

In other Prothena Corp. news, Director Dennis J. Selkoe sold 5,000 shares of the business’s stock in a transaction on Tuesday, May 24th. The shares were sold at an average price of $45.00, for a total value of $225,000.00. Following the completion of the transaction, the director now owns 3,025 shares in the company, valued at $136,125. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Several institutional investors have bought and sold shares of the company. State Board of Administration of Florida Retirement System boosted its stake in Prothena Corp. by 4.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 17,358 shares of the company’s stock valued at $1,182,000 after buying an additional 803 shares during the period. Morgan Stanley boosted its stake in Prothena Corp. by 10.8% in the fourth quarter. Morgan Stanley now owns 18,747 shares of the company’s stock valued at $1,278,000 after buying an additional 1,830 shares during the period. ProShare Advisors LLC boosted its stake in Prothena Corp. by 11.1% in the fourth quarter. ProShare Advisors LLC now owns 29,906 shares of the company’s stock valued at $2,037,000 after buying an additional 2,990 shares during the period. Rhumbline Advisers boosted its stake in Prothena Corp. by 7.5% in the fourth quarter. Rhumbline Advisers now owns 30,805 shares of the company’s stock valued at $2,098,000 after buying an additional 2,140 shares during the period. Finally, New York State Common Retirement Fund boosted its stake in Prothena Corp. by 4.0% in the fourth quarter. New York State Common Retirement Fund now owns 31,000 shares of the company’s stock valued at $2,111,000 after buying an additional 1,200 shares during the period.

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.